Search

Your search keyword '"Andersen, Mads Hald"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Andersen, Mads Hald" Remove constraint Author: "Andersen, Mads Hald" Topic cancer vaccines Remove constraint Topic: cancer vaccines
38 results on '"Andersen, Mads Hald"'

Search Results

1. State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.

2. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.

3. Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.

4. Tumor microenvironment antigens.

5. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.

6. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.

7. IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status.

8. Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.

9. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.

10. Characterization of TGFβ-specific CD4 + T cells through the modulation of TGFβ expression in malignant myeloid cells.

11. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.

12. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses.

13. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.

14. [Therapeutic cancer vaccination for treatment of haematological cancers].

15. The T-win® technology: immune-modulating vaccines.

16. Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.

17. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.

18. The Balance Players of the Adaptive Immune System.

19. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.

20. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.

21. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.

22. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.

23. Immunotherapy for metastatic colorectal cancer: present status and new options.

24. Therapeutic cancer vaccines in combination with conventional therapy.

25. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.

26. RhoC a new target for therapeutic vaccination against metastatic cancer.

27. Cancer treatment: the combination of vaccination with other therapies.

28. Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil?

29. Regulators of apoptosis: suitable targets for immune therapy of cancer.

30. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.

31. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.

34. Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses.

35. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.

36. Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.

37. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.

38. Indoleamine 2,3-dioxygenase vaccination.

Catalog

Books, media, physical & digital resources